With so much at stake, there is no room for compromise. Edwards SAPIEN 3 TAVI helps you:

Deliver outcomes you demand


death or disabling stroke at 1 year1

Perfect the pathway through efficient procedures


of patients discharged to the comfort of their home1

Control for the future to continue to meet the emerging needs of new patient populations


successful post-TAVI coronary access2

For more info

Download Brochure

The valve designed to meet your Higher Standard.

Scroll / swipe side to side to review timeline

*On the primary endpoint of death, stroke, and rehospitalization at 1 year.

Clinical Study


patients studied in Edwards clinical trials

Real world experience


patients treated worldwide with Edwards TAVI valves

Data on file at Edwards Lifesciences.

Stay informed


1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019.
2. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7).
3. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010.
4. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016.
5. Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.